Akkermansia muciniphila is a next-generation probiotic with significant application
prospects. The role of A. muciniphila in metabolic diseases and tumor immunotherapy has …

Fecal microbiota transplantation (FMT) has been used as a core therapy for treating
dysbiosis-related diseases by remodeling gut microbiota. The methodology and technology …

Objective While fecal microbiota transplantation is demonstrated to improve symptoms of
autism spectrum disorder (ASD), it remains unclear whether additional treatment courses …

Fecal microbiota transplantation (FMT) is a promising treatment for microbiota dysbiosis
associated diseases, such as Clostridioides difficile infection (CDI) and inflammatory bowel …

Akkermansia muciniphila is a promising probiotic in the gut. This study aimed to determine
the presence and abundance of Akkermansia in patients with inflammatory bowel disease …

Health and well-being are important components of the United Nations Sustainable
Development Goals. Research on microbiota and human health is a burning question in …

The safety, quantitative method and delivery of faecal microbiota transplantation (FMT) vary
a lot from different countries in practice. Recently, the improved methodology of FMT based …

Background Increasing evidence shows that alterations in gut microbiome (GM) contribute to
the development of type 2 diabetes mellitus (T2DM), and fecal microbiota transplantation …

Cardiovascular diseases (CVDs) remain the major public health concern worldwide. Over
the last two decades, a considerable amount of literature has been published on gut …

Aim. Increasing evidence supports the role of the gut microbiota in the etiology of ulcerative
colitis (UC). Fecal microbiota transplantation (FMT) is a highly effective treatment against …